Yahoo Finance·2025-12-08 14:21Core Insights - Abbott Laboratories and Eli Lilly reported Q3 earnings showcasing contrasting healthcare strategies, with Abbott achieving steady growth through medical devices and Lilly experiencing explosive growth driven by GLP-1 drugs [3][4]. Financial Performance - Abbott's revenue grew by 6.9% year-over-year, with medical devices increasing by 14.8% to $5.45 billion. The company met EPS estimates at $1.30, while operating income rose 13.1% to $2.06 billion, but net income remained flat [4][9]. - Eli Lilly's revenue surged by 54% year-over-year to $17.60 billion, exceeding estimates by 9.5%. Key products Mounjaro and Zepbound generated $6.52 billion (up 109%) and $3.57 billion (up 184%), respectively. Net income skyrocketed by 475% to $5.58 billion, with an operating margin of 48.3% [5][6][9]. Guidance and Outlook - Abbott reaffirmed its guidance for 7.5-8.0% organic growth, excluding COVID testing revenue [4][9]. - Eli Lilly raised its full-year revenue guidance to $63.0-63.5 billion and non-GAAP EPS to $23.00-23.70 [5][6]. Business Strategy - Abbott diversifies its risk across various segments including medical devices, diagnostics, nutrition, and branded generics, limiting upside but cushioning downside [7]. - Eli Lilly focuses heavily on incretin-based therapies, with Mounjaro and Zepbound contributing over $10 billion in quarterly revenue. The company is expanding manufacturing capacity to meet demand [8]. Market Valuation - Eli Lilly trades at a P/E ratio of 49.5x, while Abbott trades at 15.71x, reflecting differing market expectations and growth trajectories [9].